| Literature DB >> 19669202 |
Danniele Holanda1, Merry Y Zhao, Aaron P Rapoport, Michael Garofalo, Qing Chen, X Frank Zhao.
Abstract
Primary gastric T cell lymphoma is rare and mostly of large cell type. In this paper, we present a case of gastric T cell lymphoma morphologically similar to the gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT). Morphologically, the cells are small with abundant clear cytoplasm. Lymphoepithelial lesions are readily identified with diffuse destruction of gastric glands. Immunohistochemically, the neoplastic cells are CD3+/CD4+/CD8-/Granzyme B-. Molecular studies revealed monoclonal T cell receptor gamma gene rearrangement. Clinically, the patient responded initially to four cycles of R-CHOP, but then progressed. Because peripheral T cell lymphoma is usually associated with a poor prognosis, whereas marginal zone B cell lymphoma is an indolent lymphoproliferative disorder, this morphologic mimicry should be recognized and completely investigated when atypical small lymphoid infiltrates with lymphoepithelial lesions are encountered in the stomach.Entities:
Year: 2008 PMID: 19669202 PMCID: PMC2712325 DOI: 10.1007/s12308-008-0006-8
Source DB: PubMed Journal: J Hematop ISSN: 1865-5785 Impact factor: 0.196
Fig. 1Morphologic comparison between the current primary GTCL and a B cell MALT lymphoma (H&E, ×400 amplification). Similar lymphoepithelial lesions are present in both GTCL (a) and MALT lymphoma (b)
Fig. 2Lymphoepithelial lesions of the primary GTCL (antipancytokeratin immunoperoxidase stain, ×400 amplification)
Fig. 3Molecular studies of the primary GTCL before and after the radiation therapy. DNAs from gastric biopsies before and after radiotherapy were isolated for PCR amplification using primers for T cell receptor γ gene. Lane 1 monoclonal control, lane 2 initial diagnostic biopsy, lane 3 3-month follow-up biopsy, lane 4 polyclonal control, lane 5 oligoclonal control, lane 6 5% sensitivity monoclonal control, lane 7 25-bp DNA marker (Invitrogen, Carlsbad, CA, USA)
Fig. 4Morphologic changes of the primary GTCL after the radiation therapy (H&E, × 400 amplification). a The large neoplastic cells show hyperchromatic giant nuclei in a background of acute inflammation (at 2 1/2 weeks after radiation); b rare large atypical T cells are present (arrow) in a background of reactive lymphoplasmacytosis (at 3 months after radiation)
Summary of reported cases of primary GTCL
| Casea | Age/sex | Diagnosis | Immunophenotype | Reference |
|---|---|---|---|---|
| 1 | 66/F | HG primary GTCL | CD2+/CD4+/CD8−/CD30− | [ |
| 2 | 18/M | HG primary GTCL | CD2+/CD4+/CD8− | [ |
| 3 | 46/M | Primary GTCL, large cell | CD3+/CD4+/CD8−/CD30+/ALK-1−/TIA-1+/CD103−/EBER(−) | [ |
| 4 | 62/M | Primary GTCL, large cell | CD3+/CD4+/CD8−/CD30−/CD56−/TIA-1−/EBER(−) | [ |
| 5 | 49/F | Primary GTCL, large cell | CD3+/CD4−/CD8+/CD30+/ALK-1−/TIA-1+/EBER(+) | [ |
| 6 | 47/F | Primary GTCL, large cell | CD3+/CD4−/CD8−/CD30−/CD56−/TIA-1+/EBER(−) | [ |
| 7 | 75/M | Primary GTCL, mixed small and large | CD3+/CD4+/CD8− | [ |
| 8 | 24/M | Primary GTCL, NK-like | CD3+/CD8±/CD56+/TCR+/ | [ |
| 9 | 73/F | Primary GTCL, cytotoxic | CD3+/CD4±/CD8+/CD30−/CD56±/TIA-1+/Granzyme B+/Perforin+/HTLV-1(−)/ | [ |
| 10 | 47/F | Primary GTCL, cytotoxic | CD3+/CD4−/CD8−/CD30−/TIA-1+/Granzyme B+/EBER(−) | [ |
| 11 | 56/M | Primary GTCL, pleomorphic | CD3+/CD4−/CD8−/TIA-1+/CD30+/Granzyme B+/Perforin+/CD103+/ | [ |
| 12 | 41/M | Primary GTCL, pleomorphic | CD3+/CD4+/CD8−/TIA-1−/CD30+/Granzyme B−/ | [ |
| 13 | 33/M | Primary GTCL, pleomorphic mixed cell | CD3+/CD4−/CD8+/CD30−/CD56+/TIA-1+/Perforin−/Granzyme B+/EBV(+)/HTLV(−) | [ |
| 14 | 58/M | Primary GTCL, diffuse pleomorphic | CD3+/CD4+/CD8−/CD16+/CD30±/CD103−/EBER(−)/HTLV-1(−)/ | [ |
| 15 | 62/M | Primary GTCL, diffuse pleomorphic | CD3+/CD4+/CD8−/CD16,56+/CD30+/CD103−/EBER(−)/HTLV-1(−)/ | [ |
| 16 | 45/M | Primary GTCL, mixed cell | CD3+/CD4+/CD8−/CD30+/CD56−/ALK-1−/TIA-1−/EBER(−) | [ |
| 17 | 66/M | Primary GTCL, mixed cell | CD3+/CD4+/CD8−/CD30+/CD56−/TIA-1+/EBER(−) | [ |
| 18 | 64/M | Primary GTCL, mixed cell | CD3+/CD4+/CD8−/CD30+/ALK-1−/TIA-1+/CD103−/EBER(+) | [ |
| 19 | 70/M | Primary GTCL, mixed cell | CD3+/CD4−/CD8+/CD30−/CD56−/ALK−/TIA-1−/EBER(−) | [ |
| 20 | 62/F | Primary GTCL, mixed cell | CD3+/CD4−/CD8−/CD30+/ALK-1−/TIA-1−/CD103−/EBER(−) | [ |
| 21 | 51/M | Primary GTCL, medium-sized | CD3+/CD4+/CD8−/CD30+/CD56−/ALK-1−/TIA-1+/EBER(−) | [ |
| 22 | 44/M | Primary GTCL, medium-sized | CD3+/CD4−/CD30−/CD56−/TIA-1−/EBER(−) | [ |
| 23 | 76/F | Primary GTCL, medium-sized | CD3+/CD4+/CD8+/CD30−/CD56−/CD103+/TIA-1+/Perforin−/Granzyme B−/EBV(−)/HTLV(−) | [ |
| 24 | 52/M | Primary GTCL, small- and medium-sized | CD3+/CD4+/CD8− | [ |
| 25 | 73/M | Primary GTCL, small cell | CD3+/CD45RO+/HTLV-1(−) | [ |
| 26 | 51/M | Primary GTCL, small cell | CD3+/CD4+/CD8−/CD30−/CD56−/HTLV-1(−)/ | This case |
ALK-1: anaplastic lymphoma kinase 1, EBV: Epstein–Barr virus, EBER: EBV early RNA, GTCL: gastric T cell lymphoma, HG: high grade, HTLV-1: human T cell leukemia virus type 1, TCR: T cell receptor, TIA-1: T cell intracellular antigen 1
aOnly the HTLV-1(−) cases with detailed immunohistochemical studies were included in this table.
Classification of primary GTCL
| Subtypes | Helper/inducer T cell | Cytotoxic/suppressor T cell |
|---|---|---|
| CD3 | + | + |
| CD4 | + | − |
| CD8 | − | +/− |
| CD56 | − | −/+ |
| CD103 | − | +/− |
| Granzyme B | − | +/− |
| TIA-1 | −/+ | + |
TIA-1: T cell intracellular antigen 1